miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 15, 2026

Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu

View original at globenewswire.com
Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu MAINZ, Deutschland, 15…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Forward-looking statements in this press release are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

    60% confidence

  • BioNTech aims to sustainably improve treatment options for people with cancer and develop innovative drugs with tumor-cross-cutting or synergistic potential to address cancer across all stages of the disease.

    60% confidence

  • Readers are advised to review Risk Factors in BioNTech's Form 6-K report for the period ending March 31, 2026, and subsequent SEC filings.

    60% confidence

  • BioNTech is intensifying its focus on its growing late-stage oncology pipeline while continuing early research and development aimed at long-term innovations.

    60% confidence

Data points we hold from this source

BioNTech SE · supervisory board size8 members
BioNTech SE · shareholder attendance92 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu — Source | Via News | es.VIA.NEWS